Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

KATSEYE: 11 Things You Didn't Know About the Global Girl Group From their Coachella debut to their new GAP collection, HYBE and Geffen's girl group KATSEYE has been taking over. Here are 11 things you ...

Fastly is a cautious Buy, driven by successful cross-selling of high-margin security services and margin expansion. FSLY’s edge architecture offers superior latency and logic capabilities versus AWS, ...

The M5 Pro chip introduces a range of notable advancements in performance and efficiency, setting a new standard for high-performance processors. With a redesigned core architecture, enhanced AI and ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Andy is a seasoned technology journalist with more than 15 years experience in the mobile industry, writing for Digital Trends, Wired, and more. Andy has reviewed hundreds of smartphones and tablets, ...

A new study finds that certain patterns of AI use are driving cognitive fatigue, while others can help reduce burnout. by Julie Bedard, Matthew Kropp, Megan Hsu, Olivia T. Karaman, Jason Hawes and ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...